Metabolic Modeling Combined With Machine Learning Integrates Longitudinal Data and Identifies the Origin of LXR-Induced Hepatic Steatosis

Abstract

Temporal multi-omics data can provide information about the dynamics of disease development and therapeutic response. However, statistical analysis of high-dimensional time-series data is challenging. Here we develop a novel approach to model temporal metabolomic and transcriptomic data by combining machine learning with metabolic models. ADAPT (Analysis of Dynamic Adaptations in Parameter Trajectories) performs metabolic trajectory modeling by introducing time-dependent parameters in differential equation models of metabolic systems. ADAPT translates structural uncertainty in the model, such as missing information about regulation, into a parameter estimation problem that is solved by iterative learning. We have now extended ADAPT to include both metabolic and transcriptomic time-series data by introducing a regularization function in the learning algorithm. The ADAPT learning algorithm was (re)formulated as a multi-objective optimization problem in which the estimation of trajectories of metabolic parameters is constrained by the metabolite data and refined by gene expression data. ADAPT was applied to a model of hepatic lipid and plasma lipoprotein metabolism to predict metabolic adaptations that are induced upon pharmacological treatment of mice by a Liver X receptor (LXR) agonist. We investigated the excessive accumulation of triglycerides (TG) in the liver resulting in the development of hepatic steatosis. ADAPT predicted that hepatic TG accumulation after LXR activation originates for 80% from an increased influx of free fatty acids. The model also correctly estimated that TG was stored in the cytosol rather than transferred to nascent very-low density lipoproteins. Through model-based integration of temporal metabolic and gene expression data we discovered that increased free fatty acid influx instead of de novo lipogenesis is the main driver of LXR-induced hepatic steatosis. This study illustrates how ADAPT provides estimates for biomedically important parameters that cannot be measured directly, explaining (side-)effects of pharmacological treatment with LXR agonists.

Kinetic Modeling of Saccharomyces cerevisiae Central Carbon Metabolism: Achievements, Limitations, and Opportunities

“…A commonly used approach with dynamic models is L1 or Tikhonov regularization, which adds a penalty on parameters that deviate from a specific value, favoring the estimates that resemble experimental measurements [124][125][126][127]. Furthermore, to deal with big scale kinetics models, multiple toolboxes have been developed that assist in the development and analysis of this large-scale models [128][129][130][131], and benchmarking studies have evaluated their performance in different setups [14,132], which will help the modeler select the tool that is best suited for a particular problem.…”

In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications

“…The authors identified fructokinase as a molecular target of the fructose pathway and predicted its suppression would revert lipid accumulation. Van Riel et al. (2020) used instead a machine learning algorithm, informed by metabolomic and transcriptomic time-series, to predict the metabolic response induced by treatment with a Liver X Receptor (LXR) agonist.…”

Strategies to gain novel Alzheimer’s disease diagnostics and therapeutics using modulators of ABCA transporters

“… 335 These findings were paralleled by an increase of Abca1 mRNA and ABCA1 protein content, 335 suggesting a potential relevance of TO901217 in AD therapy, although it must be taken into account that LXR activators, in particular TO901317, were demonstrated to have severe side effects in mice, such as neutropenia, hypertriacylglycerolemia, hepatic triacylglycerol accumulation, and hepatic steatosis. 271 , 346 , 347 …”